Analysis patient adherence to the antineoplastic oral therapy treatement in the chemotherapy pharmacy at hospital of Mato Grosso do Sul

Abstract

Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.Breast cancer is the leading cause of death due to neoplasm in the female gender. Adjuvant hormone therapy is an important ally in breast cancer treatment because it improves survival and decreases the recurrence of neoplasm. Tamoxifen has been widely used in patients with breast cancer who present positive estrogen receptor (ER) for up to 5 years. Patient treatment acceptance is an important component of pharmaceutical care. This study aims to analyze patient adherence to the antineoplastic oral therapy treatment in the chemotherapy pharmacy at Regional Hospital of Mato Grosso do Sul. This is a retrospective descriptive observational study from July to December 2016, conducted with patients older than 18 years (n = 95) using hormone therapy with Tamoxifen. Results: It was observed that most of the patients were in the age range of 42-60 years, single, white and coming from Campo Grande. In the study, 30.5% of the patients stopped withdrawing the medication in any of the evaluated months. The participation of the pharmacist jointly the multidisciplinary team and the patient is essential in managing side effects, adverse reactions and promotion of adherence.

Keywords

• Adesão à medicação
• Modulador Seletivo dos Receptores de Estrógeno
• Neoplasia da Mama
• Atenção Farmacêutica.